Daniel O’Connell
Director/Board Member at Aristea Therapeutics, Inc.
Profile
Daniel O’Connell currently works at Aristea Therapeutics, Inc., as Director from 2022.
Dr. O’Connell also formerly worked at Bristol Myers Squibb Co., as Executive Director-Corporate Development, Arisaph Pharmaceuticals, Inc., as Associate Director-Cardiovascular Research, LogicBio Therapeutics, Inc., as Independent Director from 2017 to 2020, Arix Bioscience Plc, as Investment Director from 2016 to 2019, PreciThera, Inc., as Director from 2017 to 2019, OrbiMed Advisors LLC, as Associate from 2012 to 2016, and OrbiMed Advisors Private Equity, as Associate.
Dr. O’Connell received his undergraduate degree from Massachusetts Institute of Technology and graduate degree and doctorate degree from Tufts University School of Medicine.
Daniel O’Connell active positions
Companies | Position | Start |
---|---|---|
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Director/Board Member | 2022-08-23 |
Former positions of Daniel O’Connell
Companies | Position | End |
---|---|---|
LOGICBIO THERAPEUTICS, INC. | Director/Board Member | 2020-12-09 |
ARIX BIOSCIENCE PLC | Chief Investment Officer | 2019-06-30 |
PreciThera, Inc.
PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Director/Board Member | 2019-06-30 |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Corporate Officer/Principal | 2016-07-31 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Analyst | - |
Training of Daniel O’Connell
Massachusetts Institute of Technology | Undergraduate Degree |
Tufts University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARIX BIOSCIENCE PLC | Finance |
Private companies | 6 |
---|---|
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Finance |
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
PreciThera, Inc.
PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Health Technology |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Health Technology |
- Stock Market
- Insiders
- Daniel O’Connell